You are here

  • Home
  • Archive
  • Volume 5, Issue 12
  • Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)

Citation Tools

Article menu

Download PDFPDF

XML
Paediatrics
Protocol
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Aoyagi R, Hamada H, Sato Y, et al
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
BMJ Open 2015;5:e009562. doi: 10.1136/bmjopen-2015-009562